



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/812,238	03/29/2004	Kishore K. Wary	D6563	3362

7590 04/03/2006

Dr. Benjamin Adler
ADLER & ASSOCIATES
8011 Candle Lane
Houston, TX 77071

EXAMINER

HADDAD, MAHER M

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 04/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10/8/2, 238

EXAMINER

Maher Haddad

ART UNIT	PAPER
----------	-------

1644

20060322

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed 1/17/06 to include SEQ ID NO: 42 in response to Office Action mailed 9/30/05, is acknowledged. However, the computer readable form of the the "Sequence Listing" submitted on 1/17/06 is flawed technically. Please see enclosed Raw Sequence Listing Error Report.

Since the above -mention Amendment and response appear to be a bona fide attempt to reply, applicant is given a TIME PERIOD OF (1) MONTH OR THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 9:00 am to 5:30 p.m. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The IFW official Fax number is (571) 273-8300.

Any information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free)

Maher Haddad

Maher Haddad, 1644

March 22, 2006

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

10/82, 238

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☒ 7. See attached Raw Sequence Listing Error Report.
Other: _____

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.



IFW16

RAW SEQUENCE LISTING

DATE: 01/17/2006

PATENT APPLICATION: US/10/812,238C

TIME: 15:30:18

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

3 <110> APPLICANT: Wary, Kishore, K.
 4 Humtsoe, Joseph O.
 6 <120> TITLE OF INVENTION: Uses of Vascular Endothelial Growth Factor
 7 and Type I Collagen Inducible Protein (VCIP)
 9 <130> FILE REFERENCE: D6563
 C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/812,238C
 12 <141> CURRENT FILING DATE: 2004-03-29
 14 <150> PRIOR APPLICATION NUMBER: US 60/458,164
 15 <151> PRIOR FILING DATE: 2003-03-27
 17 <160> NUMBER OF SEQ ID NOS: 42
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 15
 22 <212> TYPE: PRT
 23 <213> ORGANISM: Unknown
 25 <220> FEATURE:
 26 <221> NAME/KEY: CHAIN
 27 <223> OTHER INFORMATION: peptide used to raise anti-VCIP-cyto-C16
 28 antibody
 30 <400> SEQUENCE: 1
 31 Leu Ser Pro Val Asp Ile Ile Asp Arg Asn Asn His His Asn Met
 32 5 10 15
 35 <210> SEQ ID NO: 2
 36 <211> LENGTH: 20
 37 <212> TYPE: PRT
 38 <213> ORGANISM: Unknown
 40 <220> FEATURE:
 41 <221> NAME/KEY: CHAIN
 42 <223> OTHER INFORMATION: peptide used to raise anti-VCIP-RGD antibody
 44 <400> SEQUENCE: 2
 45 Glu Gly Tyr Ile Gln Asn Tyr Arg Cys Arg Gly Asp Asp Ser Lys
 46 5 10 15
 47 Val Gln Glu Ala Arg
 48 20
 51 <210> SEQ ID NO: 3
 52 <211> LENGTH: 33
 53 <212> TYPE: DNA
 54 <213> ORGANISM: Artificial Sequence
 56 <220> FEATURE:
 57 <221> NAME/KEY: primer_bind
 58 <223> OTHER INFORMATION: forward primer for VCIP
 60 <400> SEQUENCE: 3
 61 ggaggatccc tcgcgccgca gccagcgcca tgc 33
 64 <210> SEQ ID NO: 4

*see items 2 and 4
 on Ena summary
 sheet*
**Does Not Comply
 Corrected Diskette Needed**
pp 2, 6-8

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING **ERROR REPORT**

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/812,238C
Source: 1FW/6
Date Processed by STIC: 1/17/06

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 4.4.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/10/06

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION


SERIAL NUMBER:

10/8/2,238C

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☐ **Wrapped Nucleics**
Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 ☒ **Invalid Line Length** The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 ☐ **Misaligned Amino**
Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 ☒ **Non-ASCII** The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 ☐ **Variable Length** Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 ☐ **PatentIn 2.0**
"bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 ☐ **Skipped Sequences**
(OLD RULES) Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 ☐ **Skipped Sequences**
(NEW RULES) Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 9 ☐ **Use of n's or Xaa's**
(NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 ☐ **Invalid <213>**
Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 ☐ **Use of <220>** Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 ☐ **PatentIn 2.0**
"bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 ☐ **Misuse of n/Xaa** "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



IFW16

RAW SEQUENCE LISTING

DATE: 01/17/2006

PATENT APPLICATION: US/10/812,238C

TIME: 15:30:18

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

3 <110> APPLICANT: Wary, Kishore, K.
 4 Humtsoe, Joseph O.
 6 <120> TITLE OF INVENTION: Uses of Vascular Endothelial Growth Factor
 7 and Type I Collagen Inducible Protein (VCIP)
 9 <130> FILE REFERENCE: D6563
 C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/812,238C
 12 <141> CURRENT FILING DATE: 2004-03-29
 14 <150> PRIOR APPLICATION NUMBER: US 60/458,164
 15 <151> PRIOR FILING DATE: 2003-03-27
 17 <160> NUMBER OF SEQ ID NOS: 42
 20 <210> SEQ ID NO: 1
 21 <211> LENGTH: 15
 22 <212> TYPE: PRT
 23 <213> ORGANISM: Unknown
 25 <220> FEATURE:
 26 <221> NAME/KEY: CHAIN
 27 <223> OTHER INFORMATION: peptide used to raise anti-VCIP-cyto-C16
 28 antibody
 30 <400> SEQUENCE: 1
 31 Leu Ser Pro Val Asp Ile Ile Asp Arg Asn Asn His His Asn Met
 32 5 10 15
 35 <210> SEQ ID NO: 2
 36 <211> LENGTH: 20
 37 <212> TYPE: PRT
 38 <213> ORGANISM: Unknown
 40 <220> FEATURE:
 41 <221> NAME/KEY: CHAIN
 42 <223> OTHER INFORMATION: peptide used to raise anti-VCIP-RGD antibody
 44 <400> SEQUENCE: 2
 45 Glu Gly Tyr Ile Gln Asn Tyr Arg Cys Arg Gly Asp Asp Ser Lys
 46 5 10 15
 47 Val Gln Glu Ala Arg
 48 20
 51 <210> SEQ ID NO: 3
 52 <211> LENGTH: 33
 53 <212> TYPE: DNA
 54 <213> ORGANISM: Artificial Sequence
 56 <220> FEATURE:
 57 <221> NAME/KEY: primer_bind
 58 <223> OTHER INFORMATION: forward primer for VCIP
 60 <400> SEQUENCE: 3
 61 ggaggatccc tcgcgccgca gccagcgcca tgc 33
 64 <210> SEQ ID NO: 4

*see items 2 and 4
 on Ena summary
 sheet*
**Does Not Comply
 Corrected Diskette Needed**
pp 2, 6-8

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/812,238C

DATE: 01/17/2006

TIME: 15:30:18

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

65 <211> LENGTH: 25
66 <212> TYPE: DNA
67 <213> ORGANISM: Artificial Sequence
69 <220> FEATURE:
70 <221> NAME/KEY: primer_bind
71 <223> OTHER INFORMATION: reverse primer for VCIP
73 <400> SEQUENCE: 4
74 gtggcaccta catcatgttg tgggtg 25
77 <210> SEQ ID NO: 5
78 <211> LENGTH: 22
79 <212> TYPE: DNA
80 <213> ORGANISM: Artificial Sequence
82 <220> FEATURE:
83 <221> NAME/KEY: primer_bind
84 <223> OTHER INFORMATION: forward primer for human uPAR
86 <400> SEQUENCE: 5
87 cttcctgaaa tgcgtcaaca cc 22
90 <210> SEQ ID NO: 6
91 <211> LENGTH: 22
92 <212> TYPE: DNA
93 <213> ORGANISM: Artificial Sequence
95 <220> FEATURE:
96 <221> NAME/KEY: primer_bind
97 <223> OTHER INFORMATION: reverse primer for human uPAR
99 <400> SEQUENCE: 6
100 tcatagctgg gaaaactgag gc 22
103 <210> SEQ ID NO: 7
104 <211> LENGTH: 22
105 <212> TYPE: DNA
106 <213> ORGANISM: Artificial Sequence
108 <220> FEATURE:
109 <221> NAME/KEY: primer_bind
110 <223> OTHER INFORMATION: forward primer for ?-actin
112 <400> SEQUENCE: 7
113 ggctgtgcta tccctgtacg cc 22
116 <210> SEQ ID NO: 8
117 <211> LENGTH: 22
118 <212> TYPE: DNA
119 <213> ORGANISM: Artificial Sequence
121 <220> FEATURE:
122 <221> NAME/KEY: primer_bind
123 <223> OTHER INFORMATION: reverse primer for ?-actin
125 <400> SEQUENCE: 8
126 gggcagtgat ctccttctgc at 22
129 <210> SEQ ID NO: 9
130 <211> LENGTH: 23
131 <212> TYPE: DNA
132 <213> ORGANISM: Artificial Sequence
134 <220> FEATURE:

see p.6 for error
explanation

RAW SEQUENCE LISTING

DATE: 01/17/2006

PATENT APPLICATION: US/10/812,238C

TIME: 15:30:18

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

```

135 <221> NAME/KEY: primer_bind
136 <223> OTHER INFORMATION: forward primer for GAPDH
138 <400> SEQUENCE: 9
139 ggtctcctct gacttcaaca gcg      23
142 <210> SEQ ID NO: 10
143 <211> LENGTH: 24
144 <212> TYPE: DNA
145 <213> ORGANISM: Artificial Sequence
147 <220> FEATURE:
148 <221> NAME/KEY: primer_bind
149 <223> OTHER INFORMATION: reverse primer for GAPDH
151 <400> SEQUENCE: 10
152 ggtactttat tgatgggtaca tgac    24
155 <210> SEQ ID NO: 11
156 <211> LENGTH: 6
157 <212> TYPE: PRT
158 <213> ORGANISM: Unknown
160 <220> FEATURE:
161 <221> NAME/KEY: CHAIN
162 <223> OTHER INFORMATION: a peptide containing RGD sequence
164 <400> SEQUENCE: 11
165 Gly Arg Gly Asp Ser Pro
166      5
169 <210> SEQ ID NO: 12
170 <211> LENGTH: 9
171 <212> TYPE: PRT
172 <213> ORGANISM: Unknown
174 <220> FEATURE:
175 <221> NAME/KEY: CHAIN
176 <223> OTHER INFORMATION: HA-tag
178 <400> SEQUENCE: 12
179 Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
180      5
183 <210> SEQ ID NO: 13
184 <211> LENGTH: 311
185 <212> TYPE: PRT
186 <213> ORGANISM: Unknown
188 <220> FEATURE:
189 <221> NAME/KEY: CHAIN
190 <223> OTHER INFORMATION: human VCIP
192 <400> SEQUENCE: 13
193 Met Gln Asn Tyr Lys Tyr Asp Lys Ala Ile Val Pro Glu Ser Lys
194      5                      10                      15
195 Asn Gly Gly Ser Pro Ala Leu Asn Asn Asn Pro Arg Arg Ser Gly
196      20                      25                      30
197 Ser Lys Arg Val Leu Leu Ile Cys Leu Asp Leu Phe Cys Leu Phe
198      35                      40                      45
199 Met Ala Gly Leu Pro Phe Leu Ile Ile Glu Thr Ser Thr Ile Lys
200      50                      55                      60

```

RAW SEQUENCE LISTING

DATE: 01/17/2006

PATENT APPLICATION: US/10/812,238C

TIME: 15:30:18

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

```

201 Pro Tyr His Arg Gly Phe Tyr Cys Asn Asp Glu Ser Ile Lys Tyr
202                65                70                75
203 Pro Leu Lys Thr Gly Glu Thr Ile Asn Asp Ala Val Leu Cys Ala
204                80                85                90
205 Val Gly Ile Val Ile Ala Ile Leu Ala Ile Ile Thr Gly Glu Phe
206                95                100               105
207 Tyr Arg Ile Tyr Tyr Leu Lys Lys Ser Arg Ser Thr Ile Gln Asn
208                110               115               120
209 Pro Tyr Val Ala Ala Leu Tyr Lys Gln Val Gly Cys Phe Leu Phe
210                125               130               135
211 Gly Cys Ala Ile Ser Gln Ser Phe Thr Asp Ile Ala Lys Val Ser
212                140               145               150
213 Ile Gly Arg Leu Arg Pro His Phe Leu Ser Val Cys Asn Pro Asp
214                155               160               165
215 Phe Ser Gln Ile Asn Cys Ser Glu Gly Tyr Ile Gln Asn Tyr Arg
216                170               175               180
217 Cys Arg Gly Asp Asp Ser Lys Val Gln Glu Ala Arg Lys Ser Phe
218                185               190               195
219 Phe Ser Gly His Ala Ser Phe Ser Met Tyr Thr Met Leu Tyr Leu
220                200               205               210
221 Val Leu Tyr Leu Gln Ala Arg Phe Thr Trp Arg Gly Ala Arg Leu
222                215               220               225
223 Leu Arg Pro Leu Leu Gln Phe Thr Leu Ile Met Met Ala Phe Tyr
224                230               235               240
225 Thr Gly Leu Ser Arg Val Ser Asp His Lys His His Pro Ser Asp
226                245               250               255
227 Val Leu Ala Gly Phe Ala Gln Gly Ala Leu Val Ala Cys Cys Ile
228                260               265               270
229 Val Phe Phe Val Ser Asp Leu Phe Lys Thr Lys Thr Thr Leu Ser
230                275               280               285
231 Leu Pro Ala Pro Ala Ile Arg Lys Glu Ile Leu Ser Pro Val Asp
232                290               295               300
233 Ile Ile Asp Arg Asp Asn His His Asn Met Met
234                305               310
237 <210> SEQ ID NO: 14
238 <211> LENGTH: 18
239 <212> TYPE: PRT
240 <213> ORGANISM: Unknown
242 <220> FEATURE:
243 <221> NAME/KEY: CHAIN
244 <223> OTHER INFORMATION: lipid phosphatase domain of human VCIP
246 <400> SEQUENCE: 14
247 Asp Ile Ala Lys Val Ser Ile Gly Arg Leu Arg Pro His Phe Leu
248                5                10                15
249 Ser Val Cys
252 <210> SEQ ID NO: 15
253 <211> LENGTH: 18
254 <212> TYPE: PRT
255 <213> ORGANISM: Unknown

```

RAW SEQUENCE LISTING

DATE: 01/17/2006

PATENT APPLICATION: US/10/812,238C

TIME: 15:30:18

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

```

257 <220> FEATURE:
258 <221> NAME/KEY: CHAIN
259 <223> OTHER INFORMATION: a rat peptide containing lipid
260     phosphatase domain
262 <400> SEQUENCE: 15
263 Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro His Phe Leu
264             5                      10                      15
265 Ala Val Cys
268 <210> SEQ ID NO: 16
269 <211> LENGTH: 18
270 <212> TYPE: PRT
271 <213> ORGANISM: Unknown
273 <220> FEATURE:
274 <221> NAME/KEY: CHAIN
275 <223> OTHER INFORMATION: a mouse peptide containing lipid
276     phosphatase domain
278 <400> SEQUENCE: 16
279 Asp Ile Ala Lys Tyr Thr Ile Gly Ser Leu Arg Pro His Phe Leu
280             5                      10                      15
281 Ala Ile Cys
284 <210> SEQ ID NO: 17
285 <211> LENGTH: 18
286 <212> TYPE: PRT
287 <213> ORGANISM: Unknown
289 <220> FEATURE:
290 <221> NAME/KEY: CHAIN
291 <223> OTHER INFORMATION: a human peptide containing lipid
292     phosphatase domain
294 <400> SEQUENCE: 17
295 Asp Leu Ala Lys Tyr Met Ile Gly Arg Leu Arg Pro Asn Phe Leu
296             5                      10                      15
297 Ala Val Cys
300 <210> SEQ ID NO: 18
301 <211> LENGTH: 18
302 <212> TYPE: PRT
303 <213> ORGANISM: Unknown
305 <220> FEATURE:
306 <221> NAME/KEY: CHAIN
307 <223> OTHER INFORMATION: a Drosophila peptide containing lipid
308     phosphatase domain
310 <400> SEQUENCE: 18
311 Asn Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro His Phe Tyr
312             5                      10                      15
313 Thr Leu Cys
316 <210> SEQ ID NO: 19
317 <211> LENGTH: 18
318 <212> TYPE: PRT
319 <213> ORGANISM: C. elegans
321 <220> FEATURE:

```

10/8/2,238c 6

<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<221> primer_bind
<223> forward primer for β -actin

<400> 7
ggctgtgcta tccctgtacg cc 22

do not use scientific
symbols

or foreign accent
marks. They
cannot
be processed.

Please spell the
word.

This type of
error appears
in subsequent sequences.

1/8/12, 238C 7

<210> 40
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<221>

<223>

UNSURE

anti-sense primer for mouse GAPDH

? This is a peptide sequence.

<400>

40

Ser Arg Xaa Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Asp

5

10

→ This is not a sufficient explanation
for Xaa's. See
p. 8 for error
explanation.

<2217 here is not used to
explain n's or Xaa's

VARIABLE LOCATION SUMMARY

PATENT APPLICATION: US/10/812,238C

DATE: 01/17/2006

TIME: 15:30:19

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

Use of n's or Xaa's (NEW RULES):

Use of n's and/or Xaa's have been detected in the Sequence Listing.

Use of <220> to <223> is MANDATORY if n's or Xaa's are present.

in <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

Seq#:38; Xaa Pos. 2,3,4,5,6,7

Seq#:40; Xaa Pos. 3,4,5,6,7,9,10,11

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/812,238C

DATE: 01/17/2006

TIME: 15:30:19

Input Set : N:\SMITH\PTO.TAS16.txt

Output Set: N:\CRF4\01172006\J812238C.raw

L:11 M:270 C: Current Application Number differs, Replaced Current Application Number
L:586 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38 after pos.:0
L:613 M:258 W: Mandatory Feature missing, <222> Tag not found for SEQ ID#:40
L:613 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40 after pos.:0